2016
DOI: 10.1080/14756366.2016.1201813
|View full text |Cite
|
Sign up to set email alerts
|

An evolutionarily conserved allosteric site modulates beta-lactamase activity

Abstract: Declining efficiency of antibiotic-inhibitor combinatorial therapies in treating beta-lactamase mediated resistance necessitates novel inhibitor development. Allosteric inhibition offers an alternative to conventional drugs that target the conserved active site. Here, we show that the evolutionarily conserved PWP triad located at the N-terminus of the H10 helix directly interacts with the allosteric site in TEM-1 beta-lactamase and regulates its activity. While point mutations in the PWP triad preserve the ove… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
17
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 18 publications
(19 citation statements)
references
References 58 publications
2
17
0
Order By: Relevance
“…Although the novel bicyclic-boronate derivatives, including taniborbactam (which is currently undergoing phase III trials), are predicted to be highly effective in the short term, there is no certainty that resistance to these novel active site inhibitors will not emerge after several years in circulation. To work towards addressing such a risk, which history is teaching us to anticipate, this study provides supporting evidence in line with the alternative allosteric approach for inhibition of class A enzymes; a strategy which has already been receiving steady interest in TEM-1 and KPC-2 ( Horn and Shoichet, 2004 ; Meneksedag et al, 2013 ; Bowman et al, 2015 ; Avcı et al, 2016 ; Hart et al, 2016 ; Grigorenko et al, 2017 ; Galdadas et al, 2018 , 2021 ).…”
Section: Introductionsupporting
confidence: 56%
“…Although the novel bicyclic-boronate derivatives, including taniborbactam (which is currently undergoing phase III trials), are predicted to be highly effective in the short term, there is no certainty that resistance to these novel active site inhibitors will not emerge after several years in circulation. To work towards addressing such a risk, which history is teaching us to anticipate, this study provides supporting evidence in line with the alternative allosteric approach for inhibition of class A enzymes; a strategy which has already been receiving steady interest in TEM-1 and KPC-2 ( Horn and Shoichet, 2004 ; Meneksedag et al, 2013 ; Bowman et al, 2015 ; Avcı et al, 2016 ; Hart et al, 2016 ; Grigorenko et al, 2017 ; Galdadas et al, 2018 , 2021 ).…”
Section: Introductionsupporting
confidence: 56%
“…One such example is the deep mutational scan of TEM1 β-lactamase (Stiffler et al, 2015). There are residues that are distal from the active-site but are highly sensitive to substitutions, suggesting possible allostery (Avci et al, 2016). However, it is difficult to know if such mutational sensitivity is because of functional allostery or because of a decreased level of secreted protein, for example because of increased proteolysis.…”
Section: Discussionmentioning
confidence: 99%
“…the anti βlactamase activities against E. coli bacteria, 2 compounds which are A7, and A11 showed strong anti βlactamase activities resembling that of clavulanic acid, although both of them have no antibacterial activities. These compounds having one or more hydrophobic residue in its structure, this is coming true with the docking results which indicate that the selectivity for the β-lactamase enzyme increases as the compounds became more hydrophobic, as the active binding site pocket of the β-lactamase are mostly hydrophobic in nature 22 .…”
Section: Concerningmentioning
confidence: 76%